Short Interest Update on United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : The conviction of the bears is waning as is visible by the drop in the short positions from Jul 29, 2016, to August 15, 2016. The total outstanding shorts decreased from 8,794,364 to 8,420,368 shares, with 16 days to go before the expiry. The short open interest has decreased by -4.3%, amounting to a reduction of -373,996 shares. Only a handful of traders believe that the stock has a large downside from current levels, as seen in the low short interest of 20% of the float of the company. The average daily volume of the stock is 531,614 shares. The short interest information was released on Wednesday Aug 24th after the market close.

United Therapeutics Corporation (NASDAQ:UTHR): The stock opened at $129.64 on Wednesday but the bulls could not build on the opening and the stock topped out at $130.95 for the day. The stock traded down to $124.22 during the day, due to lack of any buying support eventually closed down at $124.84 with a loss of -3.70% for the day. The stock had closed at $129.64 on the previous day. The total traded volume was 616,191 shares.


In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (Chairman & CEO) of United Therapeutics Corp, Rothblatt Martine A had sold 1,249 shares worth of $156,949 in a transaction dated August 18, 2016. In this transaction, 1,249 shares were sold at $125.66 per share.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.